Evidence map›Paper›PMID 41299450›Full record

ArticleBMC biology2025

An interpretable geometric graph neural network for enhancing the generalizability of drug-target interaction prediction.

An Xiong, Zhenjie Luo, Yan Xia, Quan Zou, Leyi Wei, Zilong Zhang, Tao Wang, Lesong Wei, Feifei Cui

Abstract read
In one paragraph

Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

An XiongSchool of Computer Science and Technology, Hainan University, Haikou, 570228, China.
Zhenjie LuoSchool of Computer Science and Technology, Hainan University, Haikou, 570228, China.
Yan XiaSchool of Computer Science and Technology, Hainan University, Haikou, 570228, China.
Quan ZouInstitute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Leyi WeiCentre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Science, Macao Polytechnic University, Macao, SAR, China.
Zilong ZhangSchool of Computer Science and Technology, Hainan University, Haikou, 570228, China. zhangzilong@hainanu.edu.cn.
Tao WangLaboratory of Protein Structure and Function, Institute of Medicine and Pharmacy, Qiqihar Medical University, Qiqihar, 161006, China. wangtao@qmu.edu.cn.
Lesong WeiYangtze Delta Region Institute (Quzhou), University of Electronic Science and Technology of China, Quzhou, 324000, China. lesongwei@csj.uestc.edu.cn.
Feifei CuiSchool of Computer Science and Technology, Hainan University, Haikou, 570228, China. feifeicui@hainanu.edu.cn.

Funding

Education Department Foundation of Heilongjiang Province 2024-KYYWF-0339Hainan Provincial Natural Science Foundation of China 324MS009National Natural Science Foundation of China 62262015New Star of South China Sea NHXXRCXM202306Qiqihar Medical Institute Foundation QMSI2024Z-01Science and Technology special fund of Hainan Province ZDYF2024GXJS018Scientific Technology Project of Qiqihar City LSFGG-2024099
6 · The paper itself

Abstract

backgroundAccurate prediction of drug-target interactions (DTIs) is essential for advancing drug discovery. Although numerous computational methods have been proposed, many exhibit limited generalization, particularly when dealing with unseen drugs or targets.

resultsTo address this challenge, we introduce GPS-DTI, a deep learning framework designed to capture both local and global features of drugs and proteins, thereby enhancing predictive robustness. Specifically, GPS-DTI employs a graph isomorphism network with edge features (GINE)-based graph neural network, combined with a multi-head attention mechanism (MHAM), to effectively model the structural characteristics of drug molecules. For proteins, representations are derived from the pre-trained Evolutionary Scale Model (ESM-2) model and further refined through convolutional neural networks (CNNs), yielding rich feature embeddings. A cross-attention module integrates drug and protein features, uncovering biologically meaningful interactions and improving model interpretability.

conclusionsComprehensive benchmarking across in-domain and cross-domain DTI prediction tasks demonstrates that GPS-DTI outperforms existing methods, underscoring its strong generalization capability. Notably, the model achieves state-of-the-art performance on drug-target affinity (DTA) tasks and shows robust adaptability when evaluated on an independent Coronavirus Disease 2019 (COVID-19)-related test set. Furthermore, visualization of cross-attention maps offers interpretable insights into key molecular interactions, highlighting the potential of GPS-DTI in real-world drug discovery applications.

Indexed as

Drug DiscoveryGraph Neural NetworksConvolutional Neural NetworksDeep LearningHumansNeural Networks, ComputerPrecision MedicineProteinsSARS-CoV-2ProteinsCross-attentionDrug–target interactionGraph neural networks

Identifiers

PMID41299450
PMCPMC12659342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.